Early experience with PEF in the setting of recalcitrant stage IV lung cancer
This study suggests that PEF therapy may be associated with significantly improved PFS and OS in patients with progressive stage IV non-small cell lung cancer compared to the matched cohort. Prospective controlled studies are required to confirm these preliminary findings, to better understand the mechanism of action of PEF, and to identify which patient populations would best benefit from this therapy.
Authors
- Daniel H. Sterman (ORCID: https://orcid.org/0009-0004-0170-2722)
- Joseph Mammarappallil (ORCID: https://orcid.org/0000-0002-5175-0595)
- Priya Bhattacharji
- Abraham Chachoua
- Bradley B. Pua (ORCID: https://orcid.org/0000-0002-2837-8166)
- Mikhail Silk
- William H. Moore (ORCID: https://orcid.org/0009-0008-5860-3804)
Institutions
- Cornell University (US)
- West Heath Hospital (GB)
- Weill Cornell Medicine (US)
- New York University (US)
Publication Details
- Journal
- Lung Cancer
- Published
- 2025-05-10
- DOI
- https://doi.org/10.1016/j.lungcan.2025.108575
- Citations
- 6
- Primary Topic
- Microbial Inactivation Methods
- Type
- article
- Field-Weighted Citation Impact
- 7.40